Incretin agonists: a map of GLP-1, GIP, and glucagon research

Multi-receptor programs test whether complementary signaling can affect several metabolic processes within one molecule. The scientific question is not simply whether more receptors are better. Relative activity at each receptor, molecular exposure, studied population, trial duration, comparator, and tolerability all shape what a program can demonstrate.

Mechanistic diagrams are useful for organizing hypotheses, but clinical outcomes come from controlled human studies. Receptor activity measured in an assay cannot by itself predict the magnitude, durability, or safety of an effect in people.

Large randomized trials have reported outcomes for semaglutide and tirzepatide in defined populations, while retatrutide and mazdutide have their own phase-specific evidence bases. Compare each result with its trial design: eligibility, baseline characteristics, intervention period, estimand, missing-data handling, and adverse-event reporting.

A larger number in one paper does not prove superiority over a molecule studied in another trial. Head-to-head evidence is the strongest basis for comparative claims because separate trials can differ in participants, protocols, follow-up, behavioral support, and analysis.

Some incretin-pathway medicines have regulator-authorized indications, while other molecules or indications remain investigational. Status is specific to product, formulation, indication, jurisdiction, and date. It should be checked in official regulator records rather than inferred from a trial, press report, or social post.

This topic page intentionally omits dosing, titration, sourcing, compounding, and administration. Those decisions require approved labeling and qualified clinical care; a research classification page cannot account for individual contraindications, interactions, monitoring, or risk.